Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 8/20 | 0.64 |
| ▸ | LMNA | P02545 | 3/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.50 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.50 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15821036 | 0.86 | SIRT2 (0.60) | SIRT2LMNASMN1; SMN2HTTMAPK1 | |
| SCHEMBL6709884 | 0.86 | SIRT2 (0.64) | SIRT2LMNASMN1; SMN2HTT | |
| SCHEMBL15953843 | 0.86 | SIRT2 (0.64) | SIRT2LMNASMN1; SMN2HTTMAPK1 | |
| SCHEMBL15953307 | 0.86 | SIRT2 (0.71) | SIRT2LMNASMN1; SMN2HTTMAPK1 | |
| SCHEMBL15953453 | 0.84 | MAPK1 (0.69) | SIRT2LMNASMN1; SMN2HTTMAPK1 | |
| SCHEMBL12176908 | 0.83 | LMNA (0.60) | SIRT2LMNASMN1; SMN2HTTMAPK1 | |
| SCHEMBL15953835 | 0.83 | SIRT2 (0.66) | SIRT2LMNASMN1; SMN2HTTMAPK1 | |
| SCHEMBL15953597 | 0.82 | SMN1; SMN2 (0.55) | SIRT2LMNASMN1; SMN2HTTMAPK1 | |
| SCHEMBL3997987 | 0.80 | NR1I2 (0.61) | SIRT2 | |
| SCHEMBL7814970 | 0.80 | NR1H3 (0.74) | LMNASMN1; SMN2HTTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9890117-B2 | Benzamide compounds and related methods of use | NORTHWESTERN UNIVERSITY (US) | 2018-02-13 | — | — | US | disclosed |
| US-20170050926-A1 | Benzamide Compounds and Related Methods of Use | NORTHWESTERN UNIVERSITY | 2017-02-23 | — | — | US | disclosed |
| US-9533947-B2 | Benzamide compounds and related methods of use | NORTHWESTERN UNIVERSITY (US) | 2017-01-03 | — | — | US | disclosed |
| US-9371277-B2 | Benzamide compounds and related methods of use | NORTHWESTERN UNIVERSITY (US) | 2016-06-21 | — | — | US | disclosed |
| US-20150025235-A1 | Benzamide Compounds and Related Methods of Use | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-01-22 | — | — | US | disclosed |
| US-20140234939-A1 | Benzamide Compounds and Related Methods of Use | NORTHWESTERN UNIVERSITY (US) | 2014-08-21 | — | — | US | disclosed |
| WO-2014100833-A1 | BENZAMIDE COMPOUNDS AND RELATED METHODS OF USE | NORTHWESTERN UNIVERSITY (US) | 2014-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170050926-A1 | Benzamide Compounds and Related Methods of Use | SIRT2, SIRT1, SIRT3 | SIRT2 1/4885LMNA 1970/4885SMN1; SMN2 245/4885 |
| US-20140234939-A1 | Benzamide Compounds and Related Methods of Use | SIRT2, SIRT1, SIRT3 | SIRT2 1/4885LMNA 1970/4885SMN1; SMN2 245/4885 |
| US-20150025235-A1 | Benzamide Compounds and Related Methods of Use | SIRT2, SIRT1, SIRT3 | SIRT2 1/4885LMNA 1970/4885SMN1; SMN2 245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.